It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Executive management committee
Manuel O. Méndez joined Quotient (NASDAQ:QTNT) as the company’s Chief Executive Officer in April 2021.
He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts. Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America. An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University.
Ali Kiboro joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in November 2021.
Mr. Kiboro brings over 20 years of experience in global finance in healthcare services and manufacturing. Mr. Kiboro joined the Company from Quest Diagnostics where he served as Vice President, Finance supporting the Commercial organization. Over a 12-year career at Quest, Mr. Kiboro assumed finance positions of increasing responsibility supporting Quest’s strategy around hospitals, health plans, global markets, oncology and anatomic pathology, professional lab services and clinical trials. Prior to that, Mr. Kiboro served as a financial analyst with General Motors (GM) in 1997. He moved to GM Treasurer’s Office in roles in the US and Europe covering capital markets, corporate strategy, capital planning, mergers and acquisitions, pension and healthcare funding, and investor relations. Ali holds an MBA in Finance from The Wharton School at the University of Pennsylvania and a BS in Finance from Duquesne University.
Christian Albrich joined Quotient (NASDAQ:QTNT) as the company’s Chief People Officer in September 2021.
He brings 30 years of HR experience in the healthcare industry, designing effective and business-aligned people strategies, fostering high-performing cultures, and leading organizational development initiatives. Previously, he spent 20 years with Actelion Pharmaceuticals, now a JANSSEN Pharmaceutical company of Johnson & Johnson, where he served as the Senior Vice President and Head of Global Human Resources. Joining Actelion at the start-up phase, he transformed the HR function to support the rapid growth of the company. Prior to joining Actelion, Christian was Human Resources Director at Serono Pharmaceuticals in France and Belgium.
Mohammad El Khoury joined Quotient (NASDAQ:QTNT) as the company’s Chief Commercial Officer in October 2021.
He brings 30 years of experience in driving commercial strategies for major diagnostic portfolios some of which included, infectious disease, transfusion, digital PCR, and COVID-19 testing solutions. Mr. El Khoury joins the Company from QIAGEN (NYSE:QGEN), where he served as President, Head of Global Sales of Molecular Diagnostics leading a global team of over 600 people. He led the expansion strategies across different geographies. Prior to that, he served as Vice President, Commercial Performance at bioMérieux, leading a cross-functional international team. While there, he secured top-line profitability worldwide by driving regional go-to-market strategies and execution plans. Mr. El Khoury also brings international experience in leadership roles at Roche Diagnostics and GE Healthcare.
Dr. Christine Ginocchio joined Quotient (NASDAQ:QTNT) as the company’s Chief Scientific & Medical Officer in October 2021.
She brings 40 years of experience clinical diagnostics, laboratory management, and medical education. Dr. Ginocchio joins the Company from bioMérieux/BioFire where she held the role of Senior Vice President, Global Medical Affairs. In this capacity she directed the BioFire post-market study program, BioFire medical education and training, and provided key medical insight for new product development. Prior to joining bioMérieux/BioFire, Dr. Ginocchio directed over 150 laboratory professionals in a core facility that provided state-of-the-art diagnostic testing and research opportunities for 11 hospitals, including 3 academic centers. She was responsible for all areas of infectious disease diagnostics, including microbiology, virology, molecular diagnostics, immunology/serology, hepatitis and HIV testing services. With over 115 peer reviewed publications, Dr. Ginocchio has been a speaker at more than 250 national and international conferences and is considered an international expert in molecular diagnostics and clinical virology. She attained the rank of Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell Health, NY. Dr. Ginocchio remains active in numerous professional societies, and she is a voting member of the President’s Advisory Council for Combating Antibiotic Resistant Bacteria (PACCARB).
Dr. Michael Hausmann joined Quotient (NASDAQ:QTNT) in August 2021 to serve as the company’s Chief Technology Officer and to lead our research, product development and program management office.
Passionate about creating value through internal and external innovation and customer-centric design and development, Michael brings about 25 years of in vitro diagnostics industry experience to the Company. Prior to joining Quotient, he led Abbott Diagnostics' R&D center in Germany, global R&D for BioMérieux's immunoassay business and, most recently, global R&D for Thermo Fisher Scientific's BRAHMS biomarker business unit and Clinical Diagnostics Division. At these firms, he oversaw portfolio and program management offices, biomarker research and technology innovation as well as assay and system development programs and enabled teams to deliver numerous new product introductions to the Point-of-Care, clinical laboratory and blood transfusion markets and to accelerate growth of industry leading solutions such as Architect, Prism, Vidas and BRAHMS Procalcitonin. Michael holds a Ph.D. in Biology from the Max-Planck-Institute of Immunobiology and a MSc degree in Chemistry from Albert-Ludwigs-University in Freiburg, Germany and is an alumnus from the General Management Program of CEDEP, Fontainebleau, France.
Esteban Uriarte joined Quotient (NASDAQ:QTNT ) as the company’s Chief Manufacturing Operations Officer in February 2022.
He brings over 30 years of experience in leading high-growth teams in manufacturing and production operations management in the medical devices and pharmaceutical industries. He joins the Company from Ferring Pharmaceuticals where he served as Senior Manufacturing Director responsible for the headquarters site based in Switzerland and the LatAm region. Prior to joining Ferring Pharmaceuticals, he was the Manufacturing Director, Instruments (DACH) at Depuy Synthes, a Johnson & Johnson Company. While there he led 800 employees at five factories and was responsible for defining the global manufacturing strategic initiatives in support of footprint optimization and competitiveness improvement. He has held numerous leadership positions at companies such as Vifor Pharma, S.A., Novartis, and Medtronic. Esteban holds an MBA in Finance from Inter-American University Metropolitan Campus Puerto Rico, and a BS in Electrical Engineering from the Georgia Institute of Technology.
Hyatt Antognini joined Quotient (NASDAQ:QTNT) as the company’s Head of Corporate Communications in January 2019.
Ms. Antognini has over 8 years of experience in global and strategic communications. Previously, she worked for international organizations including the International Labour Organization; and EASL where she served as the EU public affairs focal point and managed the media house for an EU funded project for the launch of a novel liver dialysis medical device. While there, she managed a range of internal and external stakeholders and delivered strategic communications across multiple platforms. Hyatt holds a B.S. in Political Science and a Masters in Global Communications from the American University of Paris.
Michael Campbell joined Quotient (NASDAQ:QTNT) as the company’s Head of Regulatory Affairs & Quality in February 2019.
He has over 25 years of experience in quality and regulatory roles in medical device and in vitro diagnostics manufacturing. Prior to joining Quotient, Mr. Campbell worked at Occlutech Group, Maquet Cardiopulmonary, Beckman Coulter and Olympus in various leadership positions, providing leadership during development projects and external evaluations, regulatory agency interactions and authorizations and market entry/commercialization activities for products including blood grouping analyzers and reagents. Michael holds a Bachelor of Science in Biology & Chemistry from Berry College, Georgia.
Viviane Montarnal joined Quotient (NASDAQ:QTNT) as the company’s Head of Legal Affairs & Compliance in April 2020.
Viviane has over 25 years of experience as in-house counsel in the medical device and pharmaceutical sectors. Previously, she served as Vice President, Associate General Counsel for Haemonetics, which provides blood and plasma collection devices and services. Ms. Montarnal also held senior in-house legal positions at Integra LifeSciences and IPSEN, companies active in the medical device and pharmaceutical industries. Viviane holds a Master in Pharmaceutical Law from Orsay University (France), a Master in International Commercial Law from Nanterre University (France), a degree in Private Law (specialized in International Commercial Law) from University Jean-Monnet Paris XI, and is a graduate from the ISIT Paris interpretation and translation institute in English and Spanish.
Board of directors
Heino von Prondzynski, Chairman of the board of directors, served as chief executive officer of Roche Diagnostics and as a member of the executive committee of F. Hoffman-La Roche Ltd., a Swiss based healthcare company that develops diagnostics and therapeutic products, from early 2000 to 2006, retiring from Roche at the end of 2006. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including president of the vaccine business, at Chiron Corporation, a multinational biotechnology firm that developed biopharmaceuticals, vaccines and blood-testing products and was a member of the supervisory board at Koninklijke Philips Electronics NV, . Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer AG, a German based maker of healthcare products, specialty materials and agricultural products. Mr. von Prondzynski also serves on the boards of Hospira, Inc., QIAGEN NV, and Epigenomics AG. Within the past five years, Mr. von Prondzynski also has served as a director of Nobel Biocare Holding AG, Switzerland (from 2010 to 2011). Mr. von Prondzynski studied maths, geography and history at Westfälische Wilhelms University, Münster, Germany.
Manuel O. Méndez is Chief Executive Officer of Quotient and has been a member of the board of directors since April 2021. He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts. Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America. An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University.
Brian McDonough is a Director, appointed in May 2012. Mr. McDonough is presently a Principal of Dx Consulting, a consultancy specializing in transfusion diagnostics. From 2003 through 2009, Mr. McDonough was Vice President, Worldwide Marketing, Donor Screening at Ortho Clinical Diagnostics, a Johnson and Johnson company. From 2000 through 2003, he was President of the North American Blood Products Group of the Medical Division of Pall Corporation, a company specializing in medical filtration products. Prior to holding these senior executive positions, Mr. McDonough had an extensive career at the American Red Cross spanning over 30 years. From 1968 through 1982, Mr. McDonough worked in American Red Cross BioMedical Services as Executive Head of the St. Louis Regional Blood Services Unit. In 1982, he became the Executive Director of the Irwin Memorial Blood Bank of San Francisco, where he also served on several public health committees addressing the spread of AIDS. In 1987, Mr. McDonough returned to the American Red Cross as Regional Vice President of BioMedical Services and in 1994 served under Elizabeth Dole as Chief Operating Officer, Blood Services of the American Red Cross BioMedical Services, with overall responsibility for national blood and plasma programs. Brian received a B.A. in liberal arts from Wichita State University and an M.H.A. from Central Michigan University.
Dr. Catherine Larue is a Director, appointed in September 2020. Dr. Catherine Larue serves as Director of External Affairs at the Integrated Biobank of Luxemburg (IBBL), which is organized within the Luxemburg Institute of Health (LIH) and dedicated to supporting biomedical research, providing biospecimen and biobanking services and infrastructure for applied medical research. Dr. Catherine Larue began her career at Sanofi in the cardiovascular R&D department before joining Sanofi Diagnostics Pasteur in Minneapolis, Minnesota, where she was responsible for assay development on the Access instrument in the immunodiagnostic area. Dr. Larue also served as a Director of business unit at Bio-Rad Laboratories Inc., and Executive Vice President of Biomarkers at GENFIT, before serving as CEO of IBBL. Dr. Larue has authored 87 publications (h index 19) and filed 13 patents, while also creating and chairing the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She sits on the boards of Fondation ARC, an organization of public utility focused on cancer research, Genfit a biopharmaceutical company, and Information Technology for Translational Medicine (ITTM S.A.), a clinical data processing company. Dr. Larue holds a Ph.D. in immunology from the University of Rouen and a Master's in Business Administration from St. John’s University and ISM Paris.
Dr. Isabelle Buckle is a Director, appointed in September 2020. Dr. Isabelle Buckle serves as Executive Vice-President of Technology Transfer and Industrial Partnership at Institut Pasteur, a private non-profit foundation with global outreach, dedicated to research, teaching and public health initiatives in the field of emerging viruses, infections, epidemics and diseases. Dr. Isabelle Buckle has over 25 years of scientific commercial and business experience in the biotechnology sector including previously serving as Global Vice President of Clinical Mass Spectrometry at Bruker Daltonics, CEO and Chairman at InGen Biosciences (an in vitro diagnostics group headquartered in France), Global Head European Pharma’s Accounts at Life Technologies (now part of Thermo Fisher Scientific), and Regional Director Head of Business Development at Ciphergen Biosystems Inc. Dr. Buckle holds a Ph.D. in Biochemistry from the University Paris VII, Institut Pasteur.
Dr. John Wilkerson is a Director, appointed in February 2012. Dr. Wilkerson co-founded Galen Partners in 1990 and currently serves as a Senior Advisor to Galen. Dr. Wilkerson has focused on healthcare throughout his career, beginning as a Group Product Director for Ortho Diagnostics Inc., a Johnson & Johnson company. He was a Vice President covering medical device companies at Smith Barney before moving in 1980 to Channing, Weinberg & Co., Inc., a management consulting firm for pharmaceutical, diagnostic, medical device and biotechnology companies, which he purchased and renamed The Wilkerson Group (acquired by IBM in 1996). Dr. Wilkerson currently serves as a director Cardiva and TPS and was previously the Chairman of Atlantic Health Systems, a New Jersey hospital system. He is a trustee and former President of the Museum of American Folk Art and founder of the E. L. Rose Conservancy. Dr. Wilkerson received a Ph.D. from Cornell University.
Frederick Hallsworth is a Director, appointed in February 2011. Mr. Hallsworth spent 25 years with Arthur Andersen, becoming a partner in 1989. At Andersen, Mr. Hallsworth held a number of senior management positions, including Head of Corporate Finance, Head of Audit and Managing Partner of Andersen Cambridge, and Managing Partner and Head of Audit of Andersen Scotland. He joined Deloitte Scotland in 2002, where he served as Senior Client Service Partner, and Head of TMC Practice until 2005. He is also currently a director of memsstar (2006), CMA Scotland (2007), and Metaforic (2009). Former directorships include: Scottish Enterprise (2004-2010), Microvisk (2006-2012), Forth Dimension Displays (2007-2011), Elonics (2006-2010), Golden Charter (2009-2011), Infinite Data Storage plc (2005-2007), 3Way Networks (2005-2007), Innovata plc (2005-2007), and AT Communications plc (2008-2009). Mr. Hallsworth has been a Member of the Institute of Chartered Accountants of Scotland since 1978. Mr. Hallsworth received a Bachelor of Accountancy from Glasgow University 1974.
Zubeen Shroff is a Director, appointed in July 2013. Mr. Shroff is a Managing Director of Galen Partners, a leading healthcare growth equity firm founded in 1990. Mr. Shroff has 25 years of experience working with entrepreneurs and their Board of Directors in building high-growth healthcare companies. Mr. Shroff joined Galen in 1996, from The Wilkerson Group, where he was a Principal with a client base including pharmaceutical, diagnostics, device and biotech companies, plus a select number of venture capital firms. Prior to joining The Wilkerson Group, Mr. Shroff worked at Schering-Plough France, a manufacturer of healthcare products and medicines, where he helped launch their biotech product, alpha-Interferon, in several new indications. Currently, Mr. Shroff is Treasurer and on the Executive Committee of the Board for The Westchester Medical Center Public Benefit Corporation, as well as Chairman of its Foundation. Since 2004, he has served on the Advisory Committees to Boston University Medical School and The Center for Global Health & Development. In addition, Mr. Shroff is on the Advisory Board of the Joslin Diabetes Center. In addition to the above positions, over the past 10 years, Mr. Shroff has served on the Board of Directors of numerous privately held Galen portfolio companies in the industry. Mr. Shroff served on the public Board of Directors of Pet DRx Corporation until July 2010 and Encore Medical until June 2006. Mr. Shroff received a BA in Biological Sciences from Boston University and an MBA from the Wharton School, University of Pennsylvania.
Mr. Thomas Aebischer, 60, has been the chief financial officer of RWDC Ltd., a biotechnology company concentrated on innovative and cost-effective environmentally friendly biopolymer material solutions, since March, 2021. From January, 2016 to December, 2019, Mr. Aebischer served as Executive VP and CFO of LyondellBasell Industries, a company active in plastics, chemicals and refinement. Mr. Aebischer also served as chief financial officer for the Holcim Group from 2011 to 2015. Before becoming chief financial officer, he worked in various positions for Holcim including as the chief financial officer for group companies from 1996 to 2010. Earlier in his career, Mr. Aebischer held positions as tax assessor and financial auditor. Mr. Aebischer has served as a director and member of the audit committee of Dormakaba (Switzerland) since October, 2021. Mr. Aebischer is a Swiss Certified Accountant and graduated from the Advanced Management Program at Harvard Business School.
Board committee composition
Chief Financial Officer
Business Park Terre Bonne
Route de Crassier 13
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Quotient Limited board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
- Product complaints
- Product inquiries
- New product suggestions
- Resumes and other forms of job inquiries
- Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
For more information, please read our Shareholder Communication Policy.